Arbutus Biopharma Corp — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Arbutus received $178.4M (its share) from a $950M noncontingent Moderna settlement payment in July 2026, with an additional $1.3B contingent on an appellate ruling. The company returned $230M to shareholders via tender offer in early October 2026, repurchasing 46M shares (23% of outstanding) at $5.00/share. Cash position stood at $337.5M as of September 30, 2026. Additionally, the FDA lifted a clinical hold on AB-101 (oral PD-L1 inhibitor), and Arbutus expanded patent litigation against Pfizer/BioNTech with new lawsuits in Japan and amended Canadian lawsuit.
Why this rating
Settlement and capital return materially strengthen balance sheet (71% of market cap in cash); significant for clinical-stage biotech. Litigation expansion and FDA clearance support pipeline but face long timelines.
Tradability signal
NO TRADE
No trade: positive news with only -1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.11% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $3.68 | +10 min · unknown $3.76 ▲ 2.17% | +30 min · unknown $3.77 ▲ 2.58% | +1 hr · unknown $3.83 ▲ 3.94% | +4 hrs · unknown $3.83 ▲ 4.08% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.